Intensive Care Medicine

, Volume 35, Issue 8, pp 1331–1336 | Cite as

PRO: hydroxyethylstarch can be safely used in the intensive care patient—the renal debate

Special Article
First Online:
Received:
Accepted:

Abstract

Introduction

Correcting hypovolemia is fundamental when treating the critically ill. Different hydroxyethylstarch (HES) preparations with different physicochemical characteristics (mean molecular weight (Mw), molar substitution (MS), C2/C6 ratio, balanced/unbalanced) are available. The possible detrimental effect of HES on kidney function has become a major objection to using HES.

Methods

This review focuses on the effect of HES on kidney function.

Results

First and second-generation HES with high Mw (>200 kD) and high MS (>0.5) have been shown to impair kidney function in some studies of septic patients, especially when using hyperoncotic HES. More rapidly degradable HES preparations (Mw 130 kD; MS < 0.5) did not cause deterioration of kidney function in a variety of clinical conditions. Even when kidney function was impaired (serum creatinine >1.5 mg/dL) this HES preparation was without negative effect. Dissolving HES in a balanced solution instead of saline may further improve the safety of HES with regard to kidney function. Dose limitations of the specific HES preparation should be carefully considered.

Conclusions

Hyperoncotic HES should not be used in patients who are at risk of developing kidney dysfunction. In patients without preexisting kidney dysfunction there seems to be no negative effects of modern HES preparations. In septic patients with reduced kidney function (serum creatinine >2.5 mg/dL) HES should be used cautiously, because studies of these patients are not available. Dissolving HES in a balanced solution further improves the safety of HES with regard to kidney function. At present, there seems to be no good reason to generally ban use of HES in our patients.

Keywords

Hydroxyethylstarch Kidney function Hypovolemia Plasma substitutes Volume replacement Organ function 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This paper was not supported by a pharmaceutical company. The author obtained funding for studies and for traveling from the following companies: B. Braun (Germany), Baxter (Europe), Fresenius Kabe (Germany), Delatselect (Germany), Bernburg (Germany), Edwards (Europe).

References

  1. 1.
    Bagshaw SM, Bellomo R (2006) Fluid resuscitation and the septic kidney. Curr Opin Crit Care 12:527–530PubMedCrossRefGoogle Scholar
  2. 2.
    Mills GH (2007) Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? Br J Anaesth 98:157–159PubMedCrossRefGoogle Scholar
  3. 3.
    Cussak RJ, Ball JAS, Rhodes A, Grounds RM (2002) Improving postoperative morbidity and mortality. Intensivmed 39:571–577CrossRefGoogle Scholar
  4. 4.
    Bunn F, Trivedi D, Ashraf S (2008) Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev CD001319Google Scholar
  5. 5.
    Perel P, Roberts I (2007) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev CD000567Google Scholar
  6. 6.
    Schortgen F, Deye N, Brochard L, CRYCO Study Group (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 30:2222–2229PubMedCrossRefGoogle Scholar
  7. 7.
    Jungheinrich C, Neff TA (2005) Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 44:681–699PubMedCrossRefGoogle Scholar
  8. 8.
    Legendre C, Thervet E, Page B, Percheron A, Noël LH, Kreis H (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342:248–249PubMedCrossRefGoogle Scholar
  9. 9.
    Iana A, Schwartz D (1994) Renal tubular cellular and molecular events in acute renal failure. Nephron 68:413–418CrossRefGoogle Scholar
  10. 10.
    Rozich JD, Paul RV (1989) Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 87:358–360CrossRefGoogle Scholar
  11. 11.
    Moran M, Kapsner C (1987) Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 317:150–153PubMedGoogle Scholar
  12. 12.
    Cittanova ML, LeBlanc I, Legendre C, Mouquet C, Riou B, Coriat P (1996) Effects of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348:1620–1622PubMedCrossRefGoogle Scholar
  13. 13.
    Winkelmayer WC, Glynn RJ, Levin R (2003) Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 64:1046–1049PubMedCrossRefGoogle Scholar
  14. 14.
    Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicenter randomised study. Lancet 357:911–916PubMedCrossRefGoogle Scholar
  15. 15.
    Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, German Competence Network Sepsis (SepNet) (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139PubMedCrossRefGoogle Scholar
  16. 16.
    Schortgen F, Girou E, Deye N, Brochard L, for the CRYCO Study Group (2008) The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 34:2157–2168PubMedCrossRefGoogle Scholar
  17. 17.
    Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent JL (2007) Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 98:216–224PubMedCrossRefGoogle Scholar
  18. 18.
    Boldt J, Müller M, Mentges D, Papsdorf M, Hempelmann G (1998) Volume therapy in the critically ill: is there a difference? Intensive Care Med 24:28–36PubMedCrossRefGoogle Scholar
  19. 19.
    Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C (2003) Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 29:763–769PubMedGoogle Scholar
  20. 20.
    Boldt J, Brosch C, Röhm K, Papsdorf M, Mengistu A (2008) Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac-surgery patients. Br J Anaesth 100:457–464PubMedCrossRefGoogle Scholar
  21. 21.
    Boldt J, Brosch C, Ducke M, Papsdorf M, Lehmann A (2007) Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac-surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 35:2740–2746PubMedCrossRefGoogle Scholar
  22. 22.
    Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF (2002) The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 95:544–551PubMedCrossRefGoogle Scholar
  23. 23.
    Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C (2008) Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 100:504–508PubMedCrossRefGoogle Scholar
  24. 24.
    Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R (2003) Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 96:1453–1459PubMedCrossRefGoogle Scholar
  25. 25.
    Boldt J, Brosch C, Röhm K, Lehmann A, Mengistu A, Suttner S (2008) Is albumin administration in hypoalbuminemic elderly cardiac-surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 107:1496–1503PubMedCrossRefGoogle Scholar
  26. 26.
    Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P (2008) Safety of HES 130/0.4 (Voluven) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 20:1–9Google Scholar
  27. 27.
    Wiedermann CJ (2008) Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 8:1Google Scholar
  28. 28.
    Davidson IJ (2006) Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 23:721–738PubMedCrossRefGoogle Scholar
  29. 29.
    Shatney CH, Chaudry ICH (1984) Hydroxethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis. Circ Shock 13:21–22PubMedGoogle Scholar
  30. 30.
    Waitzinger J, Bepperling F, Pabst G, Opitz J (2003) Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 4:149–157PubMedCrossRefGoogle Scholar
  31. 31.
    Jungheinrich C, Sauermann W, Bepperling F, Vogt NH (2004) Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 5:1–9PubMedCrossRefGoogle Scholar
  32. 32.
    Lehmann GB, Asskali F, Boll M, Burmeister MA, Marx G, Hilgers R, Förster H (2007) HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 98:635–644PubMedCrossRefGoogle Scholar
  33. 33.
    Ragaller MJ, Theilen H, Koch T (2001) Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 17:S33–S39Google Scholar
  34. 34.
    Honore PM, Joannes-Boyau O, Boer W (2008) Hyperoncotic colloids in shock and risk of renal injury: enough evidence for a banning order? Intensive Care Med 34:2127–2129PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Anesthesiology and Intensive Care MedicineKlinikum der Stadt LudwigshafenLudwigshafenGermany

Personalised recommendations